文献速递胸部肿瘤

MARIPOSA研究:评估至症状性进展时间这一患者相关疗效终点

Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer.
PubMed 文献 · Eur J Cancer · 2026-07-09

MARIPOSA是一项3期随机研究,比较amivantamab联合lazertinib与奥希替尼在既往未治疗、EGFR突变晚期NSCLC中的疗效。至症状性进展时间(TTSP)作为次要终点被量化评估,定义为从随机化至疾病特异性症状加重需临床干预或治疗改变或死亡的时间。最终OS分析时(中位随访37.8个月),联合组中位TTSP为43.6个月,奥希替尼组为29.3个月(HR 0.69;95%CI 0.57-0.83;p<0.0001)。

要点

  • amivantamab联合lazertinib较奥希替尼显著延长TTSP。
  • TTSP与PFS和OS均呈强相关。
  • TTSP整合患者感知的症状加重,补充传统终点。

核心结论

  • amivantamab联合lazertinib较奥希替尼显著延迟至症状性进展时间。
  • TTSP与PFS和OS高度相关,提供互补的疗效信息。

研究设计与样本

  • MARIPOSA为3期随机研究,TTSP作为次要疗效终点进行定量评估。
  • TTSP定义为从随机化至疾病特异性症状加重需临床干预或治疗改变或死亡的时间。

主要发现

  • 最终协议指定的OS分析时(中位随访37.8个月),联合组中位TTSP为43.6个月,奥希替尼组为29.3个月(HR 0.69;95%CI 0.57-0.83;p<0.0001)。
  • 联合组较奥希替尼组减少了TTSP事件后的死亡。
  • 观察到TTSP与PFS或OS之间强相关。

临床怎么用

  • TTSP可作为临床医生验证的疾病特异性症状加重测量,捕捉患者感知并促发临床行动的症状。
  • TTSP与PFS和OS高度相关,可辅助传统终点理解治疗获益并支持临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the phase 3 randomized MARIPOSA study, amivantamab and lazertinib combination therapy demonstrated improved progression-free survival (PFS) and overall survival (OS) versus osimertinib in participants with previously untreated, epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Time to symptomatic progression (TTSP) was introduced to assess clinical worsening and complement endpoints that investigate radiographic disease progression and patient-reported outcomes. TTSP provides an easily interpretable measure of disease-specific symptom worsening to further support patient experience. METHODS: In MARIPOSA, TTSP was quantitatively assessed as a secondary efficacy endpoint and defined as the time from randomization until participants experience disease-specific symptom worsening requiring a clinical intervention or treatment change, or death. To evaluate the impact of amivantamab and lazertinib on TTSP considering its established OS benefit against osimertinib, an exploratory analysis censoring death events was performed. RESULTS: At the final protocol-specified OS analysis (median follow up: 37.8 months), median TTSP was 43.6 months with amivantamab and lazertinib versus 29.3 months with osimertinib (hazard ratio [HR]: 0.69; 95% confidence interval [CI]: 0.57-0.83; p < 0.0001). Amivantamab and lazertinib reduced deaths following a TTSP event compared to osimertinib. A strong correlation between TTSP and PFS or OS was observed. CONCLUSIONS: Amivantamab and lazertinib significantly delayed TTSP versus osimertinib. TTSP offers a clinician-validated measurement of disease-specific symptom worsening, capturing symptoms perceived by patients that prompt clinical action. TTSP is highly correlated with PFS and OS, providing complementary insights alongside traditional endpoints. TTSP enhances understanding of treatment benefit and supports informed clinical decision-making by integrating patient experience.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nguyen D, Lee SH, Lu S, et al. Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer. Eur J Cancer. 2026. PMID: 42492306. doi:10.1016/j.ejca.2026.116938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。